Table 1 Main result summary

Institution type

 Non-university hospital

 University hospital

 NA

393 (49.5)

425 (50.5)

22

Gender

 Male

 Female

 Prefer not to say

 NA

328 (39.71)

493 (59.69)

5 (0.61)

14

Experience

 < 5 years

 5–10 years

 10–20 years

 > 20 years

 NA

199 (45.33)

108 (24.60)

96 (21.87)

36 (8.20)

401

Indications for pelvic MRI

 Evaluation of recurrence of pelvic tumors

 Detection and staging of gynecologic neoplasms

 Assessment of pelvic pain

 Evaluation of endometriosis

 Evaluation of sonographically indeterminate mass

 Detection and staging of other malignant tumors of the pelvis

659 (78.45)

680 (80.95)

416 (49.52)

628 (74.76)

657 (78.21)

638 (75.95)

 Eval. of fibroids

 Identification and staging of soft tissue sarcomas

 Evaluation of complications after pelvic surgery

 Identification of congenital anomalies

 Determination of arterial or venous anatomy and patency

 Assessment of pelvic defects

 Evaluation of abdominal pain in pregnant women

481 (57.26)

529 (63.00)

422 (50.23)

546 (65.00)

205 (24.40)

366 (43.57)

309 (36.78)

Use of T2/T1 sequence covering the whole paraaortic regions

 Yes

 No

 NA

483 (70.20)

205 (29.80)

152

Oblique sequence perpendicular to the axis of the uterus or cervix for endometrial or cervical cancer staging

 Yes

 No

 NA

577 (85.23)

100 (14.77)

163

Slice thickness of axial oblique sequence (< 4 mm)

 Yes

 No

 NA

395 (64.30)

221 (35.70)

224

Gadolinium T1WI FS sequence

 Yes, in every case

 No, never

 Evaluation of recurrence of pelvic tumors

 In case of detection of gynecologic neoplasms

 In case of staging of gynecologic neoplasms

 In case of assessment of a pelvic mass

 In case of evaluation of fibroids

 In case of identification of congenital anomalies

 In case of evaluation of Endometriosis

 In case of assessment of pelvic floor defects

 Other

155 (18.45)

230 (27.38)

541 (64.4)

520 (61.9)

530 (63.1)

533 (63.5)

337 (40.12)

176 (21.0)

277 (33.0)

161 (19.17)

47 (5.6)

Gadolinium cat

 No, never

 At least one

 Yes, in every case

230 (27.38)

455 (54.17)

155 (18.45)

Dynamic Contract enhanced/perfused MRI

 Yes, in every case

 No, never

 Evaluation of recurrence of pelvic tumors

 In case of detection of gynecologic neoplasms

 In case of staging of gynecologic neoplasms

 In case of assessment of a pelvic mass

 In case of evaluation of fibroids

 In case of identification of congenital anomalies

 In case of evaluation of Endometriosis

 In case of assessment of pelvic floor defects

 Other

65 (7.74)

473 (56.31)

238 (28.33)

258 (30.71)

267 (31.79)

243 (28.93)

127 (15.12)

69 (8.21)

90 (10.71)

71 (8.45)

38 (4.5)

Dynamic Contract enhanced cat

 No, never

 At least one

 Yes, in every case

473 (56.31)

302 (35.95)

65 (7.74)

DWI sequence

 Yes, in every case

 No, never

 Evaluation of recurrence of pelvic tumors

 In case of detection of gynecologic neoplasms

 In case of staging of gynecologic neoplasms

 In case of assessment of a pelvic mass

 In case of evaluation of fibroids

 In case of identification of congenital anomalies

 In case of evaluation of Endometriosis

 In case of assessment of pelvic floor defects

 Other

347(41.31)

285 (33.92)

519 (61.79)

525 (62.50)

515 (61.31)

508 (60.48)

419 (49.88)

350 (41.67)

396 (47.14)

348 (41.43)

27 (3.2)

DWI sequence cat

 No, never

 At least one

 Yes, in every case

285 (33.93)

208 (24.76)

347 (41.31)

Do you use standardized reporting?

 Yes

 No

 NA

281 (46.29)

326 (53.71)

233

Are you aware of ESUR guidelines?

 Yes

 No

 NA

290 (47.9)

315 (52.1)

235

Do you use ESUR guidelines?

 Yes

 No

 NA

290 (47.93)

315 (52.07)

235